• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    uniQure N.V. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/13/25 5:27:13 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QURE alert in real time by email
    000159056000-0000000false00015905602025-06-112025-06-11

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): June 11, 2025

    ​

    uniQure N.V.

    (Exact Name of Registrant as Specified in Charter)

    ​

    The Netherlands

      

    001-36294

      

    N/A

    (State or Other
    Jurisdiction of Incorporation)

    (Commission
    File Number)

    (IRS Employer
    Identification No.)

    ​

    Paasheuvelweg 25a,
    1105 BP Amsterdam, The Netherlands

      

    N/A

    (Address of Principal Executive Offices)

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: +31-20-566-7394

    ​

    (Former Name or Former Address, if Changed Since Last Report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ​

    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ​

    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ​

    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class:

      

    Trading Symbol(s)

      

    Name of each exchange on which registered:

    Ordinary Shares, par value €0.05 per share

    QURE

    The Nasdaq Stock Market LLC
    The Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ​

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    ​

    As described in Item 5.07, on June 11, 2025, at the 2025 Annual General Meeting of Shareholders (the “Annual Meeting”), the shareholders of uniQure N.V. (the “Company”) approved an amendment to the Company’s Amended and Restated 2014 Share Incentive Plan (the “2014 Plan”) to increase the number of ordinary shares reserved for issuance thereunder (the “Plan Amendment”). The board of directors of the Company (the “Board”) approved the Plan Amendment on April 15, 2025, and directed that the Plan Amendment be submitted to a vote of the Company’s shareholders at the Annual Meeting. The Plan Amendment became effective immediately upon its approval by shareholders at the Annual Meeting.

    ​

    A description of the 2014 Plan and the Plan Amendment are set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on April 28, 2025 (“Proxy Statement”). The foregoing description of the material terms of the 2014 Plan and the Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the 2014 Plan, as amended by the Plan Amendment, a conformed copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

    ​

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    ​

    On June 11, 2025, the Company held its Annual Meeting. There were 54,748,496 ordinary shares entitled to vote or be voted. 39,203,211 ordinary shares were voted in person or by proxy at the Annual Meeting.

    ​

    The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which are described in the Proxy Statement.

    ​

    Voting Proposal 1 - Resolution to adopt the 2024 Dutch statutory annual accounts and treatment of the results. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    34,060,570

    ​

    15,827

    ​

    5,909

    ​

    5,120,905

    ​

    Voting Proposal 2 - Resolution to discharge liability of the members of the Board. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    33,986,333

    ​

    75,344

    ​

    20,629

    ​

    5,120,905

    ​

    Voting Proposal 3 - Reappointment of Robert Gut as non-executive director. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    33,950,518

    ​

    106,055

    ​

    25,733

    ​

    5,120,905

    ​

    Voting Proposal 4 - Reappointment of Matthew Kapusta as executive director. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    33,948,169

    ​

    111,825

    ​

    22,312

    ​

    5,120,905

    ​

    Voting Proposal 5 - Reappointment of Jeremy Springhorn as non-executive director. This proposal was approved as set forth below.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    30,341,790

    ​

    3,709,321

    ​

    31,195

    ​

    5,120,905

    ​

    ​

    ​

    ​

    ​

    Voting Proposal 6 - Resolution to authorize sthe Board to issue ordinary shares and grant rights to subscribe for ordinary shares. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    33,902,912

    ​

    162,094

    ​

    17,300

    ​

    5,120,905

    ​

    Voting Proposal 7 - Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of ordinary shares and granting of rights to subscribe for ordinary shares. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    33,588,995

    ​

    476,539

    ​

    16,772

    ​

    5,120,905

    ​

    Voting Proposal 8 - Resolution to reauthorize the Board to repurchase ordinary shares. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    33,979,374

    ​

    92,426

    ​

    10,506

    ​

    5,120,905

    ​

    Voting Proposal 9 - Resolution to appoint KPMG Accountants N.V. as external auditors of the Company for the financial year 2025. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    39,177,095

    ​

    14,254

    ​

    11,862

    ​

    0

    ​

    Voting Proposal 10 - Resolution to approve, on an advisory basis, the compensation of the named executive officers of the Company. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    32,363,219

    ​

    1,599,559

    ​

    119,528

    ​

    5,120,905

    ​

    Voting Proposal 11 - Resolution to approve the Plan Amendment and authorize the Board to issue ordinary shares and grant rights to subscribe for ordinary shares pursuant to the 2014 Plan (as amended by the Plan Amendment). This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    31,696,861

    ​

    2,105,666

    ​

    279,779

    ​

    5,120,905

    ​

    Based on the foregoing votes, the shareholders re-elected Matthew Kapusta as an executive director and Dr. Robert Gut and Dr. Jeremy Springhorn as non-executive directors, each to serve until the 2028 annual general meeting of shareholders of the Company, and approved all other proposals set forth on the agenda for the Annual Meeting.

    ​

    Item 9.01 Financial Statements and Exhibits

    ​

    (d)Exhibits

    ​

    ​

    ​

    ​

    Exhibit No.

    ​

    Description

    ​

    ​

    ​

    10.1

    ​

    Amended and Restated 2014 Share Incentive Plan of uniQure N.V. (conformed to include the Amendment to the Amended and Restated 2014 Share Incentive Plan attached as Appendix A to the Proxy Statement)

    ​

    ​

    ​

    104

    ​

    Cover Page Interactive Data File (embedded with the Inline XBRL document).

    ​

    ​

    ​

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    ​

     

    UNIQURE N.V.

     

     

     

     

     

    Date: June 13, 2025

    By:

    /s/ Jeannette Potts

     

     

    Jeannette Potts

     

     

    Chief Legal and Compliance Officer

    ​

    ​

    Get the next $QURE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QURE

    DatePrice TargetRatingAnalyst
    4/1/2025$38.00Buy
    Chardan Capital Markets
    12/10/2024Outperform → Strong Buy
    Raymond James
    10/10/2024$20.00Outperform
    Raymond James
    2/29/2024$8.00Buy → Neutral
    Goldman
    12/19/2023$52.00 → $10.00Buy → Neutral
    Mizuho
    3/17/2022$40.00Neutral → Buy
    UBS
    12/17/2021$75.00 → $58.00Strong Buy → Outperform
    Raymond James
    10/27/2021$66.00Outperform
    William Blair
    More analyst ratings

    $QURE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

      ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O'Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O'Keefe will lead the development and execution of uniQure's global commercialization strategy for AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease. Her responsibilities include all commercial functions and medical affairs. Ms. O'K

      6/11/25 8:00:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

      ~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington's disease. Following recent Type B meetings and further guidance from the U.S. Food and Drug Administration (FDA), the Company has reached alignment with the FDA on several key components of the statistical analysis

      6/2/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

      ~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & Diagnostics Development Symposium (ETDD) ~ LEXINGTON, Mass. and AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the presentation of a clinical case study of the first participant dosed in the first cohort of its ongoing Phase I/IIa trial of an investigational gene therapy candidate, AMT-260, in patients with refractory MTLE. The data are being

      5/29/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets resumed coverage on uniQure with a new price target

      Chardan Capital Markets resumed coverage of uniQure with a rating of Buy and set a new price target of $38.00

      4/1/25 8:05:22 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure upgraded by Raymond James

      Raymond James upgraded uniQure from Outperform to Strong Buy

      12/10/24 11:36:55 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on uniQure with a new price target

      Raymond James resumed coverage of uniQure with a rating of Outperform and set a new price target of $20.00

      10/10/24 8:37:20 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Post Leonard E was granted 7,970 units of Ordinary Shares, increasing direct ownership by 33% to 32,049 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      6/13/25 5:07:11 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kaye Jack was granted 7,970 units of Ordinary Shares, increasing direct ownership by 55% to 22,551 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      6/13/25 5:01:15 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Jacques Rachelle Suzanne was granted 7,970 units of Ordinary Shares, increasing direct ownership by 35% to 30,458 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      6/13/25 4:55:00 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    SEC Filings

    See more
    • uniQure N.V. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - uniQure N.V. (0001590560) (Filer)

      6/13/25 5:27:13 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - uniQure N.V. (0001590560) (Filer)

      6/2/25 8:25:16 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by uniQure N.V.

      SCHEDULE 13G - uniQure N.V. (0001590560) (Subject)

      5/15/25 8:00:10 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Leadership Updates

    Live Leadership Updates

    See more
    • uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

      ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O'Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O'Keefe will lead the development and execution of uniQure's global commercialization strategy for AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease. Her responsibilities include all commercial functions and medical affairs. Ms. O'K

      6/11/25 8:00:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

      NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

      5/19/25 8:00:00 AM ET
      $AKTX
      $CRBP
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

      LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately. He will report to Matt Kapusta, Chief Executive Officer of uniQure, and will be based in the Company's Basel, Switzerland office. Dr. Abi-Saab will be responsible for leading all clinical research and development, regulatory affairs, medical affairs, and program management at uniQure. With Dr. Abi-Saab's appointment, Dr. Ricardo Dolmetsch becomes President and Chief Scientific Officer. He

      6/26/23 7:11:42 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Financials

    Live finance-specific insights

    See more
    • uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

      ~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington's disease. Following recent Type B meetings and further guidance from the U.S. Food and Drug Administration (FDA), the Company has reached alignment with the FDA on several key components of the statistical analysis

      6/2/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure to Announce First Quarter 2025 Financial Results

      LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial results before market open on Friday, May 9, 2025. Management will then host a conference call at 8:30 a.m. ET. As the Company advances its pipeline and AMT-130 toward a BLA submission and potential commercialization, uniQure is initiating quarterly earnings calls to provide regular updates on progress and to enhance engagement with the investment community. The event will be webcast under the Events & Presentations section of uniQure's

      5/5/25 4:05:00 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

      ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~ ~ FDA agrees that the composite Unified Huntington's Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval ~         ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Dec. 10, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company reached agreement

      12/10/24 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      11/14/24 12:01:42 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      11/13/24 4:05:14 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      10/25/24 9:48:27 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care